EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitDelphi-StudieOpen Access · CC BY 4.0

Treatment Sequencing in Metastatic HR+/HER2− Breast Cancer: A Delphi Consensus

Lazar Popović iD, Simona Borštnar, Ivana Božović-Spasojević, Ana Cvetanović, Natalija Dedić Plavetić iD, Radka Kaneva iD, Assia Konsoulova, Erika Matos iD, Snježana Tomić, Eduard Vrdoljak

Cancers · 23.04.2025 · 17 (9) · 1412

DOI: 10.3390/cancers17091412 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 23.04.2025. Verfasst von Lazar Popović und 9 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Institute of Vojvodina, Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca Balkans.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The treatment landscape in HR+/HER2− metastatic breast cancer (mBC) is continuously evolving, with evidence on new agents and combinations published almost every year. Despite updated therapeutic guidelines, second-line (2L) selection may be challenging due to clinical factors, biomarker status, and available agents.

Methods

A two-round Delphi consensus was organized in July 2024, gathering input from 10 experts in research, diagnosis, and treatment of HR+/HER2− mBC on optimal 2L and beyond choice, considering the available biomarkers and results from published clinical trials. Consensus was defined as 70% agreement or disagreement.

Results

The experts considered initially a list of 39 statements, structured into the following four sections: biomarker testing; selection of 2L treatment at progression of disease on first line endocrine therapy (ET) + CDK4/6i at ≥6 months after initiation of ET for mBC; selection of 2L treatment at disease progression on ET + CDK4/6i, at

Schlagwörter

Stichwörter der Autor:innen

Delphi consensusHR+/HER2− metastatic breast cancersecond-line therapytargeted therapytreatment choice

Autor:innen und Institutionen

  • Oncology Institute of Vojvodina, Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia.
  • Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia.
  • Institute for Oncology and Radiology of Serbia, Medical Faculty, University of Belgrade, 11000 Belgrade, Serbia.
  • University Clinical Centre Niš, Medical Faculty of Niš, 18000 Niš, Serbia.
  • University Clinical Hospital Center Zagreb, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
  • Molecular Medicine Center, Medical University of Sofia, 1431 Sofia, Bulgaria.

ORCID-Profile: Lazar Popović, Natalija Dedić Plavetić, Radka Kaneva, Erika Matos

Förderung

  • AstraZeneca Balkans

Zitieren

APA

Popović, L., Borštnar, S., Božović-Spasojević, I., Cvetanović, A., Dedić Plavetić, N., Kaneva, R., Konsoulova, A., Matos, E., Tomić, S., & Vrdoljak, E. (2025). Treatment Sequencing in Metastatic HR+/HER2− Breast Cancer: A Delphi Consensus. Cancers, 17(9), 1412. https://doi.org/10.3390/cancers17091412

Vancouver

Popović L, Borštnar S, Božović-Spasojević I, Cvetanović A, Dedić Plavetić N, Kaneva R, et al. Treatment Sequencing in Metastatic HR+/HER2− Breast Cancer: A Delphi Consensus. Cancers. 2025;17(9):1412. doi:10.3390/cancers17091412

BibTeX
@article{Popovi2025,
  author = {Popović, Lazar and Borštnar, Simona and Božović-Spasojević, Ivana and Cvetanović, Ana and Dedić Plavetić, Natalija and Kaneva, Radka and Konsoulova, Assia and Matos, Erika and Tomić, Snježana and Vrdoljak, Eduard},
  title = {Treatment Sequencing in Metastatic HR+/HER2− Breast Cancer: A Delphi Consensus},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {9},
  pages = {1412},
  doi = {10.3390/cancers17091412}
}
Kostenlos starten →